Journal of Cachexia, Sarcopenia and Muscle (JCSM) - Abstract

 Volume 3, Number 1, Page 37 - 43

Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance

Sílvia Busquets, Míriam Toledo, Marcel Orpí, David Massa, Maria Porta, Eva Capdevila, Núria Padilla, Valentina Frailis, Francisco J. López-Soriano, H. Q. Han and Josep M. Argilés


Cachexia is a multiorganic syndrome associated with cancer, characterized by body weight loss, muscle and adipose tissue wasting and inflammation.


The aim of this investigation was to examine the effect of the soluble receptor antagonist of myostatin (sActRIIB) in cachectic tumor-bearing animals analyzing changes in muscle proteolysis and in quality of life.
Administration of sActRIIB resulted in an improvement in body and muscle weights. Administration of the soluble receptor antagonist of myostatin also resulted in an improvement in the muscle force.


These results suggest that blocking myostatin pathway could be a promising therapeutic strategy for the treatment of cancer cachexia.

Busquets S., Toledo M., Orpí M., Massa D., Porta M., Capdevila E., Padilla N., Frailis V., López-Soriano F.J., Han H. Q., Argilés J.M. Ursodeoxycholic acid treatment in a rat model of cancer cachexia  J Cachex Sarcopenia Muscle 2012;1:37-43.